GlucoTrack (GCTK) Competitors $0.17 +0.00 (+0.46%) As of 02:26 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GCTK vs. VVOS, PSTV, PETV, CODX, PAVM, ICU, ALUR, SSKN, BTCY, and BSGMShould you be buying GlucoTrack stock or one of its competitors? The main competitors of GlucoTrack include Vivos Therapeutics (VVOS), Plus Therapeutics (PSTV), PetVivo (PETV), Co-Diagnostics (CODX), PAVmed (PAVM), SeaStar Medical (ICU), Allurion Technologies (ALUR), STRATA Skin Sciences (SSKN), Biotricity (BTCY), and BioSig Technologies (BSGM). These companies are all part of the "medical equipment" industry. GlucoTrack vs. Vivos Therapeutics Plus Therapeutics PetVivo Co-Diagnostics PAVmed SeaStar Medical Allurion Technologies STRATA Skin Sciences Biotricity BioSig Technologies GlucoTrack (NASDAQ:GCTK) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, community ranking, risk and media sentiment. Do analysts prefer GCTK or VVOS? Vivos Therapeutics has a consensus price target of $6.10, indicating a potential upside of 114.79%. Given Vivos Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Vivos Therapeutics is more favorable than GlucoTrack.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GlucoTrack 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Vivos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better earnings & valuation, GCTK or VVOS? GlucoTrack has higher earnings, but lower revenue than Vivos Therapeutics. Vivos Therapeutics is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGlucoTrackN/AN/A-$7.10M-$56.600.00Vivos Therapeutics$15.03M1.11-$13.58M-$2.91-0.98 Is GCTK or VVOS more profitable? GlucoTrack has a net margin of 0.00% compared to Vivos Therapeutics' net margin of -86.19%. Vivos Therapeutics' return on equity of -335.04% beat GlucoTrack's return on equity.Company Net Margins Return on Equity Return on Assets GlucoTrackN/A -826.43% -707.26% Vivos Therapeutics -86.19%-335.04%-93.58% Do insiders & institutionals believe in GCTK or VVOS? 10.9% of GlucoTrack shares are held by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are held by institutional investors. 46.5% of GlucoTrack shares are held by insiders. Comparatively, 3.0% of Vivos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community believe in GCTK or VVOS? Vivos Therapeutics received 17 more outperform votes than GlucoTrack when rated by MarketBeat users. CompanyUnderperformOutperformGlucoTrackN/AN/AVivos TherapeuticsOutperform Votes1760.71% Underperform Votes1139.29% Does the media prefer GCTK or VVOS? In the previous week, GlucoTrack and GlucoTrack both had 2 articles in the media. Vivos Therapeutics' average media sentiment score of 1.44 beat GlucoTrack's score of 1.43 indicating that Vivos Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment GlucoTrack Positive Vivos Therapeutics Positive Which has more volatility & risk, GCTK or VVOS? GlucoTrack has a beta of 0.02, indicating that its share price is 98% less volatile than the S&P 500. Comparatively, Vivos Therapeutics has a beta of 7.31, indicating that its share price is 631% more volatile than the S&P 500. SummaryVivos Therapeutics beats GlucoTrack on 11 of the 15 factors compared between the two stocks. Get GlucoTrack News Delivered to You Automatically Sign up to receive the latest news and ratings for GCTK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GCTK vs. The Competition Export to ExcelMetricGlucoTrackSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.39M$4.39B$5.56B$7.83BDividend YieldN/A39.94%5.11%4.22%P/E Ratio0.0030.6722.4818.48Price / SalesN/A54.91395.93103.60Price / CashN/A51.0838.1834.62Price / Book0.016.116.774.25Net Income-$7.10M$68.15M$3.22B$248.23M7 Day Performance6.98%-0.12%1.47%0.89%1 Month Performance-23.02%-2.24%3.99%3.53%1 Year Performance-99.68%24.15%16.15%5.08% GlucoTrack Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GCTKGlucoTrack1.8661 of 5 stars$0.17+0.5%N/A-99.7%$4.48MN/A0.005Short Interest ↓Gap DownHigh Trading VolumeVVOSVivos Therapeutics2.7879 of 5 stars$2.35+6.6%$6.10+160.1%+12.3%$13.81M$15.03M-0.41160Short Interest ↓Positive NewsGap DownPSTVPlus Therapeutics2.5829 of 5 stars$0.80+24.3%$11.50+1,342.9%-58.7%$13.72M$4.91M-0.3220PETVPetVivoN/A$0.52flatN/A-24.1%$12.59M$1.05M-1.1620Gap UpCODXCo-Diagnostics4.324 of 5 stars$0.36+0.8%$1.00+179.3%-69.7%$12.02M$3.92M-0.26100Upcoming EarningsAnalyst ForecastNews CoverageGap UpPAVMPAVmed4.4111 of 5 stars$0.68+3.0%$19.50+2,788.9%-63.8%$11.54M$3.00M-0.1690Short Interest ↓Gap UpICUSeaStar Medical0.6426 of 5 stars$1.25+3.4%N/A-89.3%$11.08M$135,000.00-0.112Short Interest ↓News CoveragePositive NewsGap UpALURAllurion Technologies3.4269 of 5 stars$2.32+1.3%$22.83+884.6%-95.2%$11.07M$32.11M-0.19501Positive NewsGap DownSSKNSTRATA Skin Sciences3.513 of 5 stars$2.63-2.1%$6.00+128.6%-40.9%$10.95M$33.56M-0.99120Short Interest ↓Positive NewsGap UpBTCYBiotricityN/A$0.43flatN/A-66.4%$10.71M$12.06M-0.4040Gap UpBSGMBioSig Technologies2.2654 of 5 stars$0.53-1.0%$2.50+372.6%-38.0%$9.12M$39,000.000.0050Positive News Related Companies and Tools Related Companies VVOS Alternatives PSTV Alternatives PETV Alternatives CODX Alternatives PAVM Alternatives ICU Alternatives ALUR Alternatives SSKN Alternatives BTCY Alternatives BSGM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GCTK) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GlucoTrack, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GlucoTrack With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GCTK Stock Free GCTK Stock Alerts